Live video webcast on Tuesday, June 18th at 3:00 PM ET HOUSTON, June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard- to-treat tumors and viruses, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 3:00 PM ET. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide an "eleva ...

Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET HOUSTON, June 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to- treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Wednesday, June 12, 2024 at 12:00 PM ET. As part of the event ...

HOUSTON, May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard- to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the EHA2024 Hybrid Congress being held June 13-16, 2024 in Madrid, Spain and virtually. Details for the poster presentation are as follows: Abstract: P537 Session: Acute myeloid leukemia – Clinical Tit ...

– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models HOUSTON, May 15, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company), a clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard- to-treat tumors and viruses, today announced ...

财务数据和关键指标变化 - 本季度R&D费用为430万美元,同比下降144万美元,主要是由于MB-106和MB-107临床试验活动减少 [12] - 本季度管理费用为240万美元,同比减少20万美元 [12] - 公司现金余额约1700万美元,市值约1300万美元,平均每日交易量3万股 [12] - 公司将一些原定2024年的支出推迟到2025年,现金可持续到2024年第四季度 [12] 各条业务线数据和关键指标变化 - 公司正在继续招募首线患者进行MB-106试验,以获取更多数据和了解 [42][43] - 首线患者的反应略好于二线患者,但样本量较小,需要更多数据支持 [42][43] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司已获得Annamycin的组成物专利保护,可至少到2040年保持市场独占地位 [6] - Annamycin在安全性和疗效方面均优于目前批准的其他蒽环类药物 [6][7] - 公司计划与FDA进行末期2期会议,申请开展100-150例二线患者的单臂注册性试验 [8][39][40] - 公司认为Annamycin的疗效数据足以支持获批,并有望成为AML治疗的新标准 [9][10][43][44] - 公司认为自身目前估值严重偏低,与同类竞争品种的估值存在巨大差距 [9][10] 管理层对经营环境和未来前景的评论 - 公司认为Annamycin的临床数据足以支持获批,并有望成为AML治疗的新标准 [6][7][8][9][10][43][44] - 公司有信心在注册性试验中重复之前的良好结果,并有望在2025年初启动该试验 [22][23][24] - 公司认为自身目前估值严重偏低,与同类竞争品种的估值存在巨大差距,未来有望得到修复 [9][10] 问答环节重要的提问和回答 问题1 **Jonathan Aschoff 提问** 除之前报告的1例过敏反应外,是否还有其他类似情况发生 [16] **Paul Waymack 回答** 除1例过敏反应外,未发现其他类似情况。该患者未能完全接受治疗,但在意图治疗分析中仍计入了未反应组 [18][21] 问题2 **Jonathan Aschoff 提问** 关于预计2025年上半年启动注册性试验,是否过于保守,是否可能提前 [22] **Walter Klemp 回答** 公司一贯保守,希望留有余地应对意外情况。技术上来说,可能在今年年底前就启动试验,但为谨慎起见,将时间定在2025年上半年 [23][24] 问题3 **Chad Yahn 提问** 请对比一下公司计划的注册性试验设计与已批准的5个二线药物的注册试验情况 [38] **Paul Waymack 回答** 已批准的5个二线药物注册试验病例数在100-300例之间,但由于反应率较低,95%置信区间不太理想。而公司计划的100例试验,由于反应率高达60%,置信区间应该足以支持批准 [39][40]

Exhibit 99.1 Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update – Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) – Also announced MB-106 reaches 20 subjects enrolled – Company to host conference call and webcast today, Monday, May 13th at 8:30 AM ET HOUSTON, May 13, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ...

– Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) – Also announced MB-106 reaches 20 subjects enrolled – Company to host conference call and webcast today, Monday, May 13th at 8:30 AM ET HOUSTON, May 13, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37758 MOLECULIN BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-4671997 (State or ...

Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, May 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to- treat tumors and viruses, today announced it has received an Issue Notification f ...

HOUSTON, May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard- to-treat tumors and viruses, today announced that it will report its financial results for the quarter ended March 31, 2024, on Friday, May 10, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, May 13, 2 ...